---

---

tags : Positive    source : Www.globenewswire.com   

save search

---

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE 4 | $42.16 1.35% 1.33% 1.3M |

Finance

| -0.61% | O: 0.78% H: 0.0% C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living

---

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
OCUL | $5.86 -22.69% -29.35% 6.1M |

Health Technology

| -4.77% | O: -5.78% H: 0.0% C: 0.0%
ocular positive for topline diabetic

---

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | News | $2.205 -2.43% -2.73% 270K |

Health Technology

| -3.0% | O: -6.87% H: 0.0% C: 0.0%
tacti-004 lung positive cancer cell for trial

---

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
MYGN | News F | $18.51 -0.7% -0.7% 640K |

Health Technology

| -2.76% | O: -2.61% H: 0.0% C: 0.0%
prequel positive for study

---

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI 1 d | $72.01 -6.1% -6.5% 4.7M |

Health Technology

| 18.82% | O: 14.75% H: 12.75% C: 6.04%
positive topline therapy results study

---

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.195 6.7% 6.28% 580K |

Health Technology

| 10.88% | O: 64.34% H: 4.82% C: -18.67%
fxr314 metabolic liver positive for results

---

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K |

Manufacturing

| -20.34% | O: -12.71% H: 0.97% C: -24.27%
t-cell positive topline trial therapeutics results

---

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
RARE | $43.38 -1.65% -1.68% 770K |

Health Technology

| -11.65% | O: -10.79% H: 0.0% C: -3.75%
gtx-102 positive treatment

---

TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
TFFP | $3.2405 -9.69% 26K |

Health Technology

| -18.39% | O: 0.25% H: 1.26% C: -11.56%
tacrolimus presentation positive sessions pharmaceuticals trial

---

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
DARE | $0.299 5.77% 5.45% 970K |

Health Technology

| 1.32% | O: 1.36% H: 0.68% C: -0.64%
ovaprene test positive bioscience publication contraceptive contraception study

---

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -8.68% -9.51% 8M |

Health Technology

| -8.77% | O: 2.92% H: 3.41% C: 2.27%
ocu400 approval positive for therapy

---

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.291 -2.15% -2.2% 27K |

Health Technology

| -22.6% | O: 3.2% H: 0.0% C: -0.28%
qn-302 association positive cancer research meeting therapeutics

---

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.36 -0.59% -0.6% 150K |

Health Technology

| -7.65% | O: 2.19% H: 6.15% C: 5.35%
metabolic positive for meeting hypertension therapeutics study

---

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
VINC | $0.8967 -5.63% -5.97% 530K |

| -80.13% | O: -65.69% H: 0.84% C: -35.37%
vip236 pharma association positive cancer pipeline research for meeting

---

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
SWAV | $327.42 -0.02% -0.02% 1.2M |

Health Technology

| 0.58% | O: 0.05% H: 0.54% C: 0.49%
positive results study

---

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
INZY | $4.57 -1.72% -1.75% 560K |

Health Technology

| -26.89% | O: 2.2% H: 7.69% C: -9.69%
inz-701 pharma positive ongoing trials topline

---

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Published: 2024-04-06 (Crawled : 16:20) - globenewswire.com
OCUL | $5.86 -22.69% -29.35% 6.1M |

Health Technology

| Email alert Add to watchlist
glaucoma ocular positive meeting

---

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
TARA | $2.705 -0.92% -0.92% 240K |

Health Technology

| -32.09% | O: 16.92% H: 11.06% C: -22.77%
tara-002 positive program therapeutics

---

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Published: 2024-04-05 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -8.68% -9.51% 8M |

Health Technology

| 0.0% | O: 1.92% H: 0.0% C: 0.0%
ocu410 armada review positive for study

---

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
TPST | $3.18 -2.75% -2.83% 320K |

Manufacturing

| -31.45% | O: 8.39% H: 2.71% C: -12.96%
tpst-1120 tumors positive cancer publication research communications trial advanced

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---